Literature DB >> 35004965

Systemic treatment of hepatocellular carcinoma: the times they are a-changin'.

Claudia Campani1,2,3, Jean-Charles Nault1,2,4,5.   

Abstract

Entities:  

Year:  2021        PMID： 35004965      PMCID： PMC8683921          DOI： 10.21037/hbsn-21-412

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  15 in total

Review 1.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Authors:  Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

2.  Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.

Authors:  Jorge A Marrero; Masatoshi Kudo; Alan P Venook; Sheng-Long Ye; Jean-Pierre Bronowicki; Xiao-Ping Chen; Lucy Dagher; Junji Furuse; Jean-Francois H Geschwind; Laura Ladrón de Guevara; Christos Papandreou; Tadatoshi Takayama; Arun J Sanyal; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Riccardo Lencioni
Journal:  J Hepatol       Date:  2016-07-25       Impact factor: 25.083

3.  Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.

Authors:  Zhenggang Ren; Jianming Xu; Yuxian Bai; Aibing Xu; Shundong Cang; Chengyou Du; Qiu Li; Yinying Lu; Yajin Chen; Yabing Guo; Zhendong Chen; Baorui Liu; Weidong Jia; Jian Wu; Junye Wang; Guoliang Shao; Bixiang Zhang; Yunfeng Shan; Zhiqiang Meng; Jianbing Wu; Shanzhi Gu; Wei Yang; Chao Liu; Xuetao Shi; Zhenyuan Gao; Tao Yin; Jiuwei Cui; Ming Huang; Baocai Xing; Yilei Mao; Gaojun Teng; Yanru Qin; Jinhai Wang; Feng Xia; Guowen Yin; Yong Yang; Mingxia Chen; Yan Wang; Hui Zhou; Jia Fan
Journal:  Lancet Oncol       Date:  2021-06-15       Impact factor: 41.316

4.  β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Pedro Molina-Sánchez; Katherine E Lindblad; Barbara Maier; Marina Ruiz de Galarreta; Daniela Sia; Marc Puigvehi; Verónica Miguela; María Casanova-Acebes; Maxime Dhainaut; Carlos Villacorta-Martin; Aatur D Singhi; Akshata Moghe; Johann von Felden; Lauren Tal Grinspan; Shuang Wang; Alice O Kamphorst; Satdarshan P Monga; Brian D Brown; Augusto Villanueva; Josep M Llovet; Miriam Merad; Amaia Lujambio
Journal:  Cancer Discov       Date:  2019-06-11       Impact factor: 39.397

5.  Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.

Authors:  Roser Pinyol; Daniela Sia; Josep M Llovet
Journal:  Clin Cancer Res       Date:  2019-01-07       Impact factor: 12.531

6.  Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study.

Authors:  Massimo Iavarone; Federica Invernizzi; Tommy Ivanics; Stefano Mazza; Claudio Zavaglia; Marco Sanduzzi-Zamparelli; Miguel Fraile-López; Carolin Czauderna; Giovanni Di Costanzo; Sherrie Bhoori; Matthias Pinter; Matteo Angelo Manini; Giuliana Amaddeo; Ainhoa Fernandez Yunquera; Federico Piñero; Maria Jose Blanco Rodríguez; Margarita Anders; Gabriel Aballay Soteras; Gerda Elisabeth Villadsen; Peter Daechul Yoon; Lucia Cesarini; Álvaro Díaz-González; Maria Luisa González-Diéguez; Raffaella Tortora; Arndt Weinmann; Vincenzo Mazzaferro; Mario Romero Cristóbal; Gonzalo Crespo; Helene Regnault; Massimo De Giorgio; Maria Varela; Rebecca Prince; Luigia Scudeller; Maria Francesca Donato; Marcus-Alexander Wörns; Jordi Bruix; Gonzalo Sapisochin; Pietro Lampertico; Maria Reig
Journal:  Liver Transpl       Date:  2021-09-16       Impact factor: 5.799

7.  Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Masafumi Ikeda; Andrew X Zhu; Max W Sung; Ari D Baron; Masatoshi Kudo; Takuji Okusaka; Masahiro Kobayashi; Hiromitsu Kumada; Shuichi Kaneko; Marc Pracht; Konstantin Mamontov; Tim Meyer; Tomoki Kubota; Corina E Dutcus; Kenichi Saito; Abby B Siegel; Leonid Dubrovsky; Kalgi Mody; Josep M Llovet
Journal:  J Clin Oncol       Date:  2020-07-27       Impact factor: 44.544

8.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

Authors:  Dominik Pfister; Nicolás Gonzalo Núñez; Roser Pinyol; Olivier Govaere; Matthias Pinter; Marta Szydlowska; Revant Gupta; Mengjie Qiu; Aleksandra Deczkowska; Assaf Weiner; Florian Müller; Ankit Sinha; Ekaterina Friebel; Thomas Engleitner; Daniela Lenggenhager; Anja Moncsek; Danijela Heide; Kristin Stirm; Jan Kosla; Eleni Kotsiliti; Valentina Leone; Michael Dudek; Suhail Yousuf; Donato Inverso; Indrabahadur Singh; Ana Teijeiro; Florian Castet; Carla Montironi; Philipp K Haber; Dina Tiniakos; Pierre Bedossa; Simon Cockell; Ramy Younes; Michele Vacca; Fabio Marra; Jörn M Schattenberg; Michael Allison; Elisabetta Bugianesi; Vlad Ratziu; Tiziana Pressiani; Antonio D'Alessio; Nicola Personeni; Lorenza Rimassa; Ann K Daly; Bernhard Scheiner; Katharina Pomej; Martha M Kirstein; Arndt Vogel; Markus Peck-Radosavljevic; Florian Hucke; Fabian Finkelmeier; Oliver Waidmann; Jörg Trojan; Kornelius Schulze; Henning Wege; Sandra Koch; Arndt Weinmann; Marco Bueter; Fabian Rössler; Alexander Siebenhüner; Sara De Dosso; Jan-Philipp Mallm; Viktor Umansky; Manfred Jugold; Tom Luedde; Andrea Schietinger; Peter Schirmacher; Brinda Emu; Hellmut G Augustin; Adrian Billeter; Beat Müller-Stich; Hiroto Kikuchi; Dan G Duda; Fabian Kütting; Dirk-Thomas Waldschmidt; Matthias Philip Ebert; Nuh Rahbari; Henrik E Mei; Axel Ronald Schulz; Marc Ringelhan; Nisar Malek; Stephan Spahn; Michael Bitzer; Marina Ruiz de Galarreta; Amaia Lujambio; Jean-Francois Dufour; Thomas U Marron; Ahmed Kaseb; Masatoshi Kudo; Yi-Hsiang Huang; Nabil Djouder; Katharina Wolter; Lars Zender; Parice N Marche; Thomas Decaens; David J Pinato; Roland Rad; Joachim C Mertens; Achim Weber; Kristian Unger; Felix Meissner; Susanne Roth; Zuzana Macek Jilkova; Manfred Claassen; Quentin M Anstee; Ido Amit; Percy Knolle; Burkhard Becher; Josep M Llovet; Mathias Heikenwalder
Journal:  Nature       Date:  2021-03-24       Impact factor: 49.962

9.  Systemic treatment of hepatocellular carcinoma: An EASL position paper.

Authors:  Jordi Bruix; Stephen L Chan; Peter R Galle; Lorenza Rimassa; Bruno Sangro
Journal:  J Hepatol       Date:  2021-07-10       Impact factor: 30.083

Review 10.  Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.

Authors:  Matthias Pinter; Bernhard Scheiner; Markus Peck-Radosavljevic
Journal:  Gut       Date:  2020-08-03       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.